Thermo Fisher Scientific
Price: 482.04Company and Business Model
Thermo Fisher Scientific is a leading provider of scientific instruments, reagents, and consumables, primarily serving the healthcare and life sciences sectors. Its core products include analytical instruments, laboratory equipment, and diagnostic tools. Major business segments encompass Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics, with revenue primarily generated from sales of laboratory equipment and reagents. The company focuses on enhancing research and clinical workflows, contributing to advancements in healthcare and scientific research.
Investment Profile
The investment profile of Thermo Fisher Scientific is more aligned with balanced investors, given its stable revenue growth and modest dividend yield. The company demonstrates consistent performance, making it suitable for those seeking a mix of capital appreciation and income. The stock's moderate volatility and solid fundamentals suggest a lower risk profile, appealing to investors with a medium to long-term horizon.
Fundamental metrics (experimental)
- EPS (TTM) — earnings per share for the last 12 months, $
- 18.22 OK
- Revenue QoQ — quarter-over-quarter revenue growth
- -9.9% ↓
- EPS surprise
- 1.9% in line
- 20d volatility
- 2.4% stable
- Dividend yield
- 0.4% low last ex-date: 2026-03-13
Track in portfolio
Price chart
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-09 02:53 | Buy | Hold | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-30 02:53 | Sell | Buy | Solid fundamentals but mixed momentum signals. |
| 2026-05-22 03:35 | Hold | Sell | Weak momentum and high risk; cautious approach advised. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-06-03 07:12 | HSBC | Update | — → 540 | 482.08 |
| 2026-05-14 20:21 | RBC Capital | Update | — → 490 | 448.21 |
| 2026-04-27 12:33 | Morgan Stanley | Target Lowered | 670 → 620 | 472.23001 |
Nothing yet